Explained · 5 min read

Cagrilintide is not a GLP-1 it’s a different appetite lever

Cagrilintide keeps getting called the next Ozempic. It isn’t chasing the same hormone at all — and the number everyone quotes for the combination isn’t the number the company was aiming for.

In this article ▾
  1. Meet amylin, the hormone GLP-1 drugs never touch
  2. Why the natural hormone never made it as a drug
  3. Two different appetite levers, not two names for the same one
  4. What the trials actually show
  5. The catch nobody puts in the thumbnail
  6. The bottom line

This is the written version of Cagrilintide vs Ozempic: Not The Fight You Think — watch it instead if you’d rather.

Ask anywhere online what cagrilintide is, and you get the same lazy answer: it’s the next Ozempic. As someone who spends a fair chunk of my working life checking whether numbers survive contact with the underlying data, that framing bothers me before I’ve even opened a single trial paper. Cagrilintide isn’t a rival to Ozempic. It isn’t even the same kind of machine.

Meet amylin, the hormone GLP-1 drugs never touch

Semaglutide, the active ingredient in Ozempic, is a GLP-1 analogue. It copies a satiety hormone released by your gut. Cagrilintide copies something else entirely: amylin, a hormone your pancreas releases alongside insulin every time you eat. Insulin manages your blood sugar; amylin’s job is to slow gastric emptying and tell your brain you’ve had enough. They clock in together, but they pull different levers on appetite.

That distinction is the whole rationale for combining the two. If GLP-1 drugs and amylin analogues worked on the same circuit, stacking them would just be belt-and-braces. They don’t, so stacking them is closer to running two independent control loops on the same process — which is exactly why Novo Nordisk built a combination drug around the idea.

Why the natural hormone never made it as a drug

If amylin is such a useful signal, why did nobody just bottle it? Because natural amylin has a design flaw: it’s chemically sticky. In people with type 2 diabetes, amylin has a tendency to clump into aggregates called amyloid, which build up in the pancreas and contribute to the loss of the very insulin-producing cells amylin is released alongside. It’s a satiety hormone that, in the wrong conditions, turns into microscopic grit inside its own factory.

That stickiness is also part of why native amylin fails as a drug candidate — it breaks down within minutes of injection. Cagrilintide is an engineered fix for both problems at once: the structure is modified and a fatty-acid chain is attached, extending its working life to roughly a week and reducing its tendency to aggregate. It’s less “the natural hormone in a vial” and more “the natural hormone re-engineered so it survives being a drug” — a distinction the hype rarely bothers to make.

Free guide · goes with this article Peptides, Plainly

The free beginner’s guide: the chemistry, maths and evidence ideas everything else rests on, explained from scratch. Comes with the other three free guides, for one email.

Get the free guides

Two different appetite levers, not two names for the same one

This is where the “next Ozempic” framing falls apart under its own weight. Cagrilintide and semaglutide aren’t competing products chasing the same receptor. They’re two separate satiety signals — gut-derived and pancreas-derived — that happen to point at the same outcome. Press one and you get an effect. Press both, and the combination drug built from them, cagrilintide plus semaglutide, is called CagriSema.

None of that makes cagrilintide a stronger Ozempic. It makes it a different tool that happens to complement Ozempic’s mechanism. That’s a genuinely interesting piece of pharmacology. It’s also a much harder story to put on a thumbnail than “next Ozempic,” which is probably why so few outlets bother telling it straight.

What the trials actually show

Here I want to slow down, because this is the part that gets rounded up in every hype thread. In its phase 2 dose-finding trial, cagrilintide on its own produced weight loss ranging from 6.0% to 10.8% at 26 weeks, depending on dose, against roughly 3% on placebo. That’s a range, not a headline number, and it sits in the same territory as older weight-loss drugs like liraglutide — solid, unspectacular.

The number everyone actually quotes, the eye-catching 22.7%, isn’t cagrilintide’s number at all. It belongs to CagriSema, the combination of cagrilintide and semaglutide, measured at 68 weeks in the REDEFINE 1 trial. That’s a real, published result, and it’s a meaningfully bigger effect than either drug produces alone. But the same result carries a second half that the highlight reel leaves out: Novo Nordisk had set its own target at 25%, and the trial fell short of it. Quote the 22.7% without that second half and you’re only telling half the story the company itself set up.

These numbers are study facts, not recommendations Where this article quotes a dose or a result, it is reporting what a specific trial gave to a specific group of people over a specific period. That is not a suggestion for anyone reading it. This article names no vendor and no source, recommends nothing, and is not medical advice.

The catch nobody puts in the thumbnail

Amylin analogues carry their own tax. Gastrointestinal side effects — nausea, constipation — show up in a substantial share of trial participants, the same family of side effects that makes GLP-1 drugs a mixed experience for plenty of people. And like every drug in this class, cagrilintide and CagriSema aren’t a one-and-done fix: stop taking a satiety-hormone drug and the appetite-suppressing effect stops with it. Exactly how much and how fast appetite returns after stopping isn’t something cagrilintide’s own trials have published a figure for — it’s a pattern seen generally across the GLP-1 and amylin drug class, and I’ve gone into that properly in my piece on coming off a GLP-1 drug rather than guessing at a number here.

The bottom line

Cagrilintide is a genuinely well-engineered piece of biology: a second appetite hormone that scientists finally worked out how to keep switched on for long enough to matter, built specifically to dodge the aggregation problem that sank the natural version. It is not a stronger Ozempic, and treating it as a rival misses what actually makes it interesting. It’s a different lever on the same overall problem — one that works best paired with, rather than instead of, the GLP-1 drugs it keeps getting compared to.

The trial data backs a measured version of that story: a solid but unspectacular result alone, a genuinely bigger result in combination, and a combination result that still missed the company’s own target. None of that is a scandal. It’s just what the numbers say when you don’t round them up. I take no money from anybody who sells peptides, so I’ve no reason to make this sound bigger, or smaller, than the papers do. If you want the GLP-1 side of this comparison, I’ve covered it in my look at retatrutide, and if you’re weighing cagrilintide against the rest of the field, it’s on my ranking of fat-loss peptides too.

Before you buy anything Peptides, Plainly is free — the free beginner’s guide: the chemistry, maths and evidence ideas everything else rests on, explained from scratch. It comes with the other three free guides for one email. If you want the full method behind them, that’s the Field-Guide Series.

Sources

  1. Lau et al., phase 2 dose-finding trial of once-weekly cagrilintide, The Lancet, 2021 — reports the cagrilintide-alone weight-loss range of 6.0% to 10.8% at 26 weeks against roughly 3% on placebo, and describes amylin as a pancreatic satiety hormone — https://doi.org/10.1016/S0140-6736(21)01751-7
  2. D'Ascanio et al., review of cagrilintide as a long-acting amylin analogue, Cardiology in Review, 2023 — explains why pairing an amylin analogue with a GLP-1 drug produces an additive appetite effect — https://doi.org/10.1097/CRD.0000000000000513
  3. Saini et al., review of islet amyloid polypeptide aggregation, Chemical Research in Toxicology, 2020 — documents how native human amylin aggregates into toxic oligomers and fibrils that contribute to pancreatic beta-cell death in type 2 diabetes — https://doi.org/10.1021/acs.chemrestox.0c00416
  4. American Diabetes Association press release on the REDEFINE 1 trial — reports the published CagriSema combination result of 22.7% mean weight loss at 68 weeks — https://diabetes.org/newsroom/press-releases/cagrisema-demonstrates-significant-weight-loss-adults-obesity
  5. HCPLive coverage of the REDEFINE 1 phase 3 results — corroborates the 22.7% weight-loss figure for the CagriSema combination at 68 weeks — https://www.hcplive.com/view/cagrisema-achieves-22-7-weight-loss-in-phase-3-redefine-1-trial
  6. PharmExec report on the REDEFINE 1 outcome — states that the CagriSema result fell short of Novo Nordisk's own stated 25% weight-loss target — https://www.pharmexec.com/view/novo-nordisk-cagrisema-falls-short-25-weight-loss-target-patients-obesity-overweight
  7. New England Journal of Medicine trial report on coadministered cagrilintide and semaglutide — the primary published combination-trial data behind the CagriSema figures — https://www.nejm.org/doi/full/10.1056/NEJMoa2502081
  8. C&EN feature on amylin-based weight-loss drugs competing with GLP-1 drugs — context on why amylin analogues are considered the next competitive front beyond GLP-1 drugs — https://cen.acs.org/pharmaceuticals/amylin-weight-loss-drugs-compete/104/web/2026/04

Educational and research purposes only — not medical advice. Peptide Corner does not recommend any vendor, source, or dose. Keep safe, keep skeptical.